Your shopping cart is currently empty

Myr5A peptide is an acylated peptide composed of an apolipoprotein A1 (ApoA1)-mimicking peptide, known as the 5A peptide, conjugated with the saturated fatty acid myristic acid. This peptide self-assembles into lipid nanostructures and has been utilized for encapsulating the anthracyclines doxorubicin and valrubicin in studies of in vitro compound release.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | Myr5A peptide is an acylated peptide composed of an apolipoprotein A1 (ApoA1)-mimicking peptide, known as the 5A peptide, conjugated with the saturated fatty acid myristic acid. This peptide self-assembles into lipid nanostructures and has been utilized for encapsulating the anthracyclines doxorubicin and valrubicin in studies of in vitro compound release. |
| Formula | C211H321N47O57 |
| Sequence | {Myr}-Asp-Trp-Leu-Lys-Ala-Phe-Tyr-Asp-Lys-Val-Ala-Glu-Lys-Leu-Lys-Glu-Ala-Phe-Pro-Asp- |
| Sequence Short | {Myr}-DWLKAFYDKVAEKLKEAFPDWAKAAYDKAAEKAKEAA |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.